Shareholders of company name have approved a total dividend payout of ₹2.50 per equity share of ₹10 each for the financial year ended March 31, 2026. The declaration was finalized during the company’s 37th Annual General Meeting (AGM) held on August 6, 2026, where members also transacted business related to director re-appointments and auditor remuneration. This dividend structure confirms a 25% payout ratio relative to the face value, signaling management’s confidence in cash flows despite the absence of disclosed profit figures in the proceedings summary.

The meeting, conducted via Video Conferencing/Other Audio Visual Means (VC/OAVM), commenced at 3:00 P.M. IST and concluded at 4:26 P.M. IST. It was held in compliance with General Circular No. 03/2025 dated September 22, 2025, issued by the Ministry of Corporate Affairs (MCA), alongside the Companies Act, 2013, and the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Sixty-six members, holding 65.60% of the company’s shares, attended the meeting, ensuring the requisite quorum was present throughout.

Key Resolutions Passed

The following ordinary and special resolutions were approved by the shareholders:

Dr. Om Tantia, Chairman and Managing Director, delivered the address, highlighting the company’s financial performance and future prospects. The statutory auditors confirmed that their report contained no qualifications, modified opinions, or adverse remarks.

Governance and Voting Details

Remote e-voting was available from August 3, 2026, to August 5, 2026, with the record date set as July 30, 2026. Mr. Ashok Kumar Daga, Practicing Company Secretary, was appointed as the Scrutinizer to oversee the voting process. The combined results of remote and during-meeting e-voting were scheduled to be communicated to the BSE and NSE within two working days of the meeting’s conclusion.

What the Numbers Show

While the specific revenue or net profit figures were not detailed in the AGM proceedings summary, the approval of a ₹1.50 final dividend on top of the ₹1 interim dividend indicates a sustained commitment to shareholder returns. The re-appointment of independent directors beyond the age of 75 (Mr. Verma) and the ratification of related-party transactions (fees for Dr. Niharika Tania and Dr. Ghanshyam Goyal) suggest a focus on continuity in governance and specialized medical consultancy support, which is critical for the healthcare sector’s operational integrity.

GPT Healthcare Limited reported a standalone net profit of ₹12.7 crore for the first quarter ended June 30, 2026, marking a 65.7% year-on-year increase from ₹7.7 crore in Q1FY26. The surge was driven by robust margin expansion, with EBITDA margins widening to 19.16% from 16.21%, and revenue growth of 17.8% to ₹1.26b Rupees. This performance underscores the company's ability to generate higher operating leverage despite rising input costs, supported by improved clinical mix and patient volumes across its network.

The Board of Directors approved the unaudited standalone financial results during a meeting held on August 3, 2026, in Kolkata. Subsequently, the company participated in an earnings conference call on August 4, 2026, at 11:00 AM (IST) to discuss these results with investors. Statutory auditors S.R. Batliboi & Co. LLP issued an unmodified limited review conclusion pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Financial Performance Highlights

The following table summarises the key standalone financial metrics for the quarter:

Earnings per share (basic and diluted) stood at ₹1.55 for the quarter, compared to ₹0.94 in Q1FY26. The company maintained its net-debt-free position, supporting sustainable returns through disciplined capital allocation. No unpublished price-sensitive information was shared during the conference call.

Operational Updates and Hospital Performance

Operational performance remained healthy, with Average Rate Per Occupied Bed (ARPOB) increasing to ₹42,350, driven by an improved clinical mix. Network occupancy stood at 58.07% overall for mature hospitals, excluding the newly commissioned Raipur facility. Including Raipur, the overall network occupancy was 45.5%. Mature hospitals continued to deliver resilient performance:

• ILS Salt Lake: Strengthened leadership in robotic-assisted surgery with over 800 cumulative procedures.
• ILS Dum Dum: Remained the highest-occupied hospital in the network, supported by its established renal transplant programme with more than 700 transplants completed. Management expects Dum Dum to reach optimum occupancy levels this year, with 70% occupancy becoming normal by Q3.
• ILS Agartala: Expanded its oncology platform with PET Scan and Linear Accelerator facilities, completing over 700 radiation therapy procedures. Management is confident that the Agartala hospital is on track to meet its original year-end occupancy target.
• ILS Howrah: Launched MAKO robotic knee replacement surgeries, supporting higher realisations.
• ILS Raipur: Commenced operations in May 2025, ramping up high-acuity specialties including oncology, cardiology, and transplant services. It received its liver transplant license.

Management Guidance and Outlook

Management shared detailed forward-looking guidance during the earnings concall. The key targets and projections are summarised below:

For the Raipur hospital, management expects to close the year at around 30% occupancy and anticipates achieving operational breakeven around the 20-month mark. The Jamshedpur hospital is expected to be commissioned in late Q4 FY27, with an initial ARPOB projected at ₹38,000–40,000 and an anticipated breakeven in approximately 24 months. The company also plans to expand its network capacity to over 1,000 beds within the next two years by evaluating opportunities for a seventh hospital.

On ARPOB growth, management noted that increases are assumed to be driven primarily by an improved specialty and case mix, which contributes 50-60% of the increase, rather than the smaller contribution from inflation-linked annual tariff revisions in October. Additionally, international patient inflows are expected to return to pre-disruption levels within the next six months, aided by policy changes requiring targeted hospital names for visa requests.

What the Numbers Show

The divergence between revenue growth and net profit growth of 65.7% highlights strong margin expansion, further reinforced by the EBITDA margin widening to 19.16% from 16.21% year-on-year. While key input costs such as materials and labor increased, they did so at a rate lower than revenue generation. This efficiency is particularly notable given the company's focus on a single reportable segment—healthcare services in India—suggesting effective pricing power or volume optimization in its service delivery model. Management's guidance of approximately 21% EBITDA margins for FY27, translating to an annual EBITDA of ₹110–115 crore, reflects confidence in sustaining this operational momentum, with long-term ROCE and ROE targets of approximately 25% anchoring the company's capital allocation strategy.